Omni Protech Drugs Pvt Ltd, headquartered in India, is a prominent player in the pharmaceutical industry, specialising in the development and manufacturing of high-quality generic medications. Established in [year founded], the company has made significant strides in operational regions across India and beyond, focusing on therapeutic areas such as cardiology, oncology, and neurology. With a commitment to innovation, Omni Protech offers a diverse range of products, including tablets, capsules, and injectables, distinguished by their rigorous quality standards and competitive pricing. The company has achieved notable recognition for its contributions to healthcare, positioning itself as a trusted partner in the pharmaceutical sector. Through its dedication to excellence and patient care, Omni Protech Drugs Pvt Ltd continues to enhance its market presence and drive advancements in medical treatments.
How does Omni Protech Drugs Pvt Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Omni Protech Drugs Pvt Ltd's score of 2 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Omni Protech Drugs Pvt Ltd, headquartered in India, currently does not report any specific carbon emissions data. However, the company has made significant climate commitments aimed at reducing its greenhouse gas (GHG) emissions. Omni Protech has set a near-term target to reduce its Scope 1 and Scope 2 emissions by 46% by 2030, using 2019 as the base year. Additionally, the company is committed to measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. In the long term, Omni Protech aims to achieve net-zero emissions by 2050, with a target to reduce total emissions (Scopes 1, 2, and 3) by 90% from the 2019 baseline. These targets have been validated through the Science Based Targets initiative (SBTi), aligning with the global goal to limit warming to 1.5°C. Omni Protech's proactive approach reflects its commitment to sustainability within the pharmaceuticals, biotechnology, and life sciences sector.
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Omni Protech Drugs Pvt Ltd is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.